Circulating tumor cells (CTCs) is an area we will continue to hear more about as their importance to our understanding prostate cancer continues to increase. CTCs show the movement of cancer cells though the body. It is believed that these CTCs are the method that cancer uses to spread through our body (metastasize). Measuring the [...]
Over the last several years’ prostate cancer treatment options for men with advanced prostate cancer has gone from rags to riches. We now have multiple options for treatment and there is every indication that the number of options will continue to grow. However, we do see that not all men will respond to all treatments. [...]
Would you be willing to trade off some survival time to lower your risk of developing bone metastases (BM)? Well, men in the UK and Sweden are willing. Men from the UK and Sweden with castrate resistant prostate cancer (CRPC) and at high risk for developing BM because they have been on androgen-deprivation (ADT) or [...]
The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]
Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival. According to a study published online ahead of print in the Journal of Clinical Oncology. by Amir Goldkorn, MD, and colleagues at the Keck School of Medicine of [...]